Drug General Information (ID: DDIW6OH2J9)
Drug Name			Abarelix		Drug Info		Efavirenz		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Anti-Hiv Agents
Structure

Mechanism of Abarelix-Efavirenz Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Abarelix				Efavirenz
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Abarelix and Efavirenz

Recommended Action
Management		alternatives to efavirenz should be considered in patients receiving other drugs that can prolong the QT interval. Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.

References
1	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.